SPRO
Spero Therapeutics Inc
1.20$
-1.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8,644.5% | -1,976.3% | -999.1% | -1,054.8% | -920.4% | -2,096.0% | -15.9% | -31.8% | -48.9% | -21.2% | |
| – | 83.3% | 18.3% | 10.3% | 15.8% | 8.2% | 21.0% | 1.8% | 0.4% | 0.0% | 0.0% | |
| – | 53.7% | 72.1% | 69.3% | 79.6% | 52.4% | 307.2% | 18.8% | 7.6% | 16.2% | 7.3% | |
| – | -882.1% | -59.3% | 85.0% | 78.4% | 48.9% | 387.7% | 32.4% | – | – | – | |
| – | -236.4% | 22.4% | -27.0% | 144.1% | -143.5% | 419.0% | 45.5% | -67.8% | 75.6% | -45.5% | |
| – | 247.8% | 1.4% | 61.4% | 6.6% | 1.7% | 2,096.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| – | -247.8% | -1.4% | -2,096.7% | 622.7% | 112.2% | 249.9% | 69.6% | – | – | – | |
| – | – | 0.0% | – | – | – | 1,546.6% | 112.2% | – | – | – | |
| – | 10,272.5% | 6,107.1% | 1,753.0% | 340.4% | 152.0% | 897.0% | 21.2% | – | – | – | |
| – | – | – | – | -1,149.0% | -584.0% | -1,774.8% | -112.2% | – | – | – | |
| – | 10,272.5% | 5,867.2% | 1,753.0% | 340.4% | 1,402.8% | 2,737.8% | -60.8% | 0.2% | 0.0% | – | |
| – | 1,380.3% | 3,889.5% | -1,342.9% | -91.7% | 594.6% | 891.7% | -7.2% | -31.6% | -48.9% | -21.2% | |
| – | -8,892.2% | -1,977.7% | -1,060.5% | -1,061.5% | -922.1% | -2,096.0% | -15.9% | -31.8% | -48.9% | -21.2% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.